Rocaltrol injections 1 mcg for secondary hyperparathyroidism (calcitriol, Calcijex, Decostriol, Vectical, Rolsical)

General information on Japanese Rocaltrol injections 1 mcg for secondary hyperparathyroidism (calcitriol, Calcijex, Decostriol, Vectical, Rolsical)

Package details: 10 vials

Manufacturer: Kyowa KirinCo., Ltd., Japan

Active ingredients: calcitriol (chemical formula C27H44O3)

Medical effect: Rocaltrol injections are effective for the treatment of secondary hyperparathyroidism in patients undergoing maintenance dialysis.

Contraindications and precautions: do not use for pregnant or breastfeeding women. Do not use for patients with vitamin D intoxication.

If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication or receiving any other treatment, you have to consult with your doctor before use.

Dosage and administration of Rocaltrol injections 1 mcg from Japan for secondary hyperparathyroidism (calcitriol)

For adults, inject intravenously at the end of each dialysis, 1-3 times a week.

Depending on patient’s response to treatment, this medicine may be used for a long period of time. The specific dosing schedule should be prescribed by the doctor in charge.

How effective are Rocaltrol injections 1 mcg from Japan for secondary hyperparathyroidism (calcitriol)?

Rocaltrol injection contain calcitriol, an active form of vitamin D, naturally produced in kidneys. It provides the following effects:

• direct and indirect suppression of synthesis and secretion of the parathyroid hormone (PTH) in the parathyroid cells,
• lowering serum PTH concentrations,
• increasing the calcium level in blood by promoting absorption of calcium from the gastrointestinal tract and increasing renal tubular reabsorption of calcium.

Who should use Rocaltrol injections 1 mcg from Japan?

Rocaltrol injections are effective for the treatment of secondary hyperparathyroidism in patients undergoing maintenance dialysis. Studies showed that 1 mcg dosage is an optimal amount of active ingredient for intravenous administration, reducing serum parathyroid hormone levels and not provoking hypercalcemia (E. R. Fischer. D. C. Harris. “Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism”. Clinical nephrology, 1993, 40(4): 216-20).